• Home
  • Search Results
  • Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.

Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.

Nature communications (2020-04-24)
Hector H Huang, Ian D Ferguson, Alexis M Thornton, Prabhakar Bastola, Christine Lam, Yu-Hsiu T Lin, Priya Choudhry, Margarette C Mariano, Makeba D Marcoulis, Chin Fen Teo, Julia Malato, Paul J Phojanakong, Thomas G Martin, Jeffrey L Wolf, Sandy W Wong, Nina Shah, Byron Hann, Angela N Brooks, Arun P Wiita

Enhancing the efficacy of proteasome inhibitors (PI) is a central goal in myeloma therapy. We proposed that signaling-level responses after PI may reveal new mechanisms of action that can be therapeutically exploited. Unbiased phosphoproteomics after treatment with the PI carfilzomib surprisingly demonstrates the most prominent phosphorylation changes on splicing related proteins. Spliceosome modulation is invisible to RNA or protein abundance alone. Transcriptome analysis after PI demonstrates broad-scale intron retention, suggestive of spliceosome interference, as well as specific alternative splicing of protein homeostasis machinery components. These findings lead us to evaluate direct spliceosome inhibition in myeloma, which synergizes with carfilzomib and shows potent anti-tumor activity. Functional genomics and exome sequencing further support the spliceosome as a specific vulnerability in myeloma. Our results propose splicing interference as an unrecognized modality of PI mechanism, reveal additional modes of spliceosome modulation, and suggest spliceosome targeting as a promising therapeutic strategy in myeloma.

Product Number
Product Description

Trifluoroacetic acid, ReagentPlus®, 99%
Acetonitrile, HPLC Plus, ≥99.9%
Anti-FLAG® M2 Magnetic Beads, affinity isolated antibody
NP-40 Alternative - CAS 9016-45-9 - Calbiochem, A non-ionic surfactant used in the isolation and purification of functional membrane protein complexes and in two-dimensional (2D) gel electrophoresis.
2-Chloroacetamide, ≥98.0% (HPLC)
2-Bromo-4-methylpyridine, 97%

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.